Mark is a seasoned medicine developer, entrepreneur, and global health leader with more than 30 years of experience spanning biotech, pharma, and academic research.
He is the Founder and Managing Director of Medicines Development for Global Health (MDGH), and previously held senior clinical leadership roles at GSK in London, Gilead Sciences in California, and as Chief Operating Officer of Australia’s vaccine design and development consortium at the University of New South Wales.
Mark has contributed to three successful global registration programs for HIV and hepatitis B therapeutics, worked across more than 40 small molecule and biologic programs, and led the development of moxidectin through FDA approval — a first for a not-for-profit medicine developer.
He was named Victorian Australian of the Year in 2019, and in 2022 was appointed Officer of the Order of Australia (AO) for his distinguished service to global health and the development of affordable medicines.